Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endo International PLC Sciences announces BEMA buprenorphine in opioid-experienced patients


Monday, 7 Jul 2014 07:00am EDT 

Endo International PLC:Announced positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients.BEMA buprenorphine is being developed for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in both patients who are opioid naive and opioid experienced.Buprenorphine resulted in significantly (p<0.0001) improved chronic pain relief compared to placebo.Additional secondary endpoints were supportive of efficacy of BEMA buprenorphine compared to placebo.Most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea (7.5 pct vs. 7.4 pct) and vomiting (5.5 pct vs. 2.3pct). 

Company Quote

70.2
 --
21 Nov 2014